Medication to stop alcohol cravings
Pro Research Analysisby 
Searched over 200M research papers
Medications to Stop Alcohol Cravings
Gabapentin for Alcohol Cravings
Gabapentin, an anticonvulsant, has shown promise in reducing alcohol consumption and cravings. In a randomized, double-blind, placebo-controlled trial, 60 male alcohol-dependent subjects were treated with gabapentin (300 mg twice daily) for 28 days. The results indicated a significant reduction in the number of drinks per day and the percentage of heavy drinking days, along with an increase in the percentage of days of abstinence compared to the placebo group. Additionally, gabapentin was well-tolerated with minimal side effects, making it a potential option for treating alcohol dependence .
Naltrexone's Role in Reducing Cravings
Naltrexone, an opioid antagonist, has been extensively studied for its efficacy in reducing alcohol cravings and consumption. In a laboratory study, alcohol-dependent individuals treated with naltrexone (50 mg daily) showed higher cortisol levels and lower craving levels compared to the placebo group. Participants on naltrexone consumed fewer drinks and reported lower levels of alcohol craving during a self-administration experiment. These findings suggest that naltrexone may reduce drinking by suppressing cravings, potentially through its effects on the hypothalamo-pituitary-adrenocortical axis . Extended-release naltrexone (XR-NTX) has also been effective in community-based treatment programs, significantly reducing alcohol cravings and use behaviors during treatment and at follow-up .
Baclofen's Efficacy in Alcohol Dependence
Baclofen, a GABA(B) receptor agonist, has demonstrated efficacy in reducing alcohol cravings and intake. In a preliminary clinical study, baclofen administered at 30 mg/day for 4 weeks significantly reduced alcohol cravings and promoted abstinence in alcoholic individuals. The drug was well-tolerated, with side effects such as headache and nausea being manageable . A double-blind, placebo-controlled study further confirmed baclofen's effectiveness in inducing and maintaining abstinence and reducing alcohol cravings in alcohol-dependent patients .
Monoamine Stabilizer OSU6162
The monoamine stabilizer OSU6162 has shown potential in reducing alcohol cravings, particularly in individuals with high baseline impulsivity. In a Phase II exploratory study, OSU6162 significantly attenuated priming-induced cravings and blunted the subjective liking of consumed alcohol. However, the study did not find significant effects on cue-induced cravings, and further research is needed to evaluate its efficacy in reducing alcohol consumption .
Combined Treatment with Oxytocin and Naltrexone
A novel approach involves combining oxytocin (OXY) with naltrexone (NTX) to reduce alcohol cravings. Preliminary studies suggest that oxytocin may enhance the effects of naltrexone, reducing alcohol craving and stress reactivity. A phase II trial is currently investigating the combined effects of intranasal oxytocin and oral naltrexone on stress-induced and alcohol cue-induced cravings in individuals with alcohol use disorder .
Conclusion
Several medications have shown efficacy in reducing alcohol cravings and consumption. Gabapentin, naltrexone, and baclofen are among the most promising, with substantial evidence supporting their use. The monoamine stabilizer OSU6162 and the combination of oxytocin and naltrexone also offer potential benefits, though further research is needed. These medications provide valuable options for individuals seeking to manage alcohol dependence and maintain abstinence.
Sources and full results
Most relevant research papers on this topic
Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial.
Gabapentin effectively reduces alcohol consumption and cravings, potentially aiding patients in maintaining abstinence and supporting its potential use in alcohol withdrawal and dependence treatment.
The effects of the monoamine stabilizer (-)-OSU6162 on craving in alcohol dependent individuals: A human laboratory study.
OSU6162 shows potential in reducing priming-induced alcohol cravings in alcohol dependent individuals, but its effect on cue-induced cravings remains unclear.
DOI